Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase ii study of depot octreotide with bevacizumab and pegylated interferon alfa-2b

Journal of Clinical Oncology

Volumn 26, Issue 8, 2008, Pages 1316-1323

  Yao, James C ^a   Phan, Alexandria ^a   Hoff, Paulo M ^a   Chen, Helen X ^a   Charnsangavej, Chusilp ^a   Yeung, Sai Ching J ^a   Hess, Kenneth ^a   Ng, Chaan ^a   Abbruzzese, James L ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CHROMOGRANIN A; INTERLEUKIN 18 BINDING PROTEIN; OCTREOTIDE; PEGINTERFERON ALPHA2B; VASCULOTROPIN; ALPHA2B INTERFERON; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 18; MONOCLONAL ANTIBODY; PEGINTERFERON ALFA-2B; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOID; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPRESSION; DIARRHEA; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INSOMNIA; LIVER METASTASIS; MALE; MYALGIA; NAUSEA; NEUTROPHIL; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; SIDE EFFECT; STOMATITIS; THORAX PAIN; THROMBOCYTE; TUMOR BLOOD FLOW; VOMITING; BLOOD; DRUG ANTAGONISM; GASTROINTESTINAL TUMOR; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; FEMALE; FIBROBLAST GROWTH FACTORS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-18; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41649114168     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.6374     Document Type: Article

References (33)

1. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934-959, 2003
2. Yao JC, Vauthey JN: Primary and metastatic hepatic carcinoid: Is there an algorithm? Ann Surg Oncol 10:1133-1135, 2003
3. Faiss S, Pape UF, Bohmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689-2696, 2003
4. Schnirer II, Yao JC, Ajani JA: Carcinoid: A comprehensive review. Acta Oncol 42:672-692, 2003
5. Klby L, Persson G, Franzen S, et al: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687-693, 2003
6. Terris B, Scoazec JY, Rubbia L, et al: Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32:133-138, 1998
7. Ambs S, Bennett WP, Merriam WG, et al: Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 78:233-239, 1998
8. Hobday TJ, Rubin J, Goldberg R, et al: Molecular markers in metastatic gastrointestinal neuroendocrine tumors. Proc Am Soc Clin Oncol 22:269a, 2003 (abstr 1078)
9. Phan AT, Wang L, Xie K, et al: Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma. J Clin Oncol 24:18s, 2006 (suppl; abstr 4091)
10. Konno H, Arai T, Tanaka T, et al: Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Japanese Journal of Cancer Res 89:933-939, 1998
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Lee TY: Functional CT: Physiological models. Trends Biotechnol 20:S3-7, 2002
13. Cascinu S: Drug therapy in diarrheal diseases in oncology/hematology patients. Crit Rev Oncol Hematol 18:37-50, 1995
14. Danesi R, Benelli U, Del Bianchi S, et al: Octreotide inhibits endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane and in the rat cornea. Proc Annu Meet Am Assoc Cancer Res, Orlando, FL, 1993 (abstr A2109)
15. Danesi R, Agen C, Benelli U, et al: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 3:265-272, 1997
16. Fazekas T, Pavics L, Pollak R, et al: [Gastric carcinoid (apudoma) associated with pernicious anemia]. Orv Hetil 129:1269-1271, 1988
17. Reubi JC, Horisberger U, Laissue J: High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction? Int J Cancer 56:681-688, 1994
18. Wang C, Tang C: Inhibition of human gastric cancer metastasis by ocreotide in vitro and in vivo [Chinese]. Zhonghua Yi Xue Za Zhi 82:19-22, 2002
19. Jia WD, Xu GL, Xu RN, et al: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 129:327-334, 2003
20. Koizumi M, Onda M, Tanaka N, et al: Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 65:200-206, 2002
21. Mentlein R, Eichler O, Forstreuter F, et al: Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 92:545-550, 2001
22. Lawnicka H, Stepien H, Wyczolkowska J, et al: Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 268:567-571, 2000
23. Buscail L, Vernejoul F, Faure P, et al: Controle de la proliferation cellulaire par la somatostatine. Ann Endocrinol 63:2S13-18, 2002
24. Adams RL, Adams IP, Lindow SW, et al: Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493-1498, 2005
25. von Marschall Z, Scholz A, Cramer T, et al: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.[comment]. J Natl Cancer Inst 95:437-448, 2003
26. Frank M, Klose KJ, Wied M, et al: Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94:1381-1387, 1999
27. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897-4904, 2005
28. Tiensuu Janson EM, Ahlstrom H, Andersson T, et al: Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28a:1647-1650, 1992
29. Janson ET, Oberg K: Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32:225-229, 1993
30. Yao JC, Zhang JX, Rashid A, et al: Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 13:234-240, 2007
31. Facco C, La Rosa S, Dionigi A, et al: High expression of growth factors and growth factor receptors in ovarian metastases from ileal carcinoids: An immunohistochemical study of 2 cases. Arch Pathol Lab Med 122:828-832, 1998
32. Kulke MH, Lenz HJ, Meropol NJ, et al: A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol 23:310s, 2005 (suppl; abstr 4008)
33. Hobday TJ, Rubin J, Holen K, et al: MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 25:4504-4505, 2007